Company profile
Celgene Corporation
Privately held: no public share price
Assets
(3 total)
3Total Assets
1Approved
1Phase 3 / Filed
1Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | Cereblon E3 ubiquitin-ligase · Thalidomide AnalogSmall molecule | Multiple Myeloma | |
Sotatercept(Winrevair) | Phase 3 | Activin receptor type IIA (ActRIIA)Protein / enzyme therapeutic | HypertensionHeart Failure |
| Phase 1/2 | mTOR (inhibitor)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.